Key facts
- Avenacy’s last known valuation is $40.0M (Dec 2024).
- It has raised $26.0M across 1 recorded rounds; the latest was Early Stage VC ($26.0M) in Nov 2024.
- Notable investors include NantWorks.
- Avenacy has filed 1 Form D with the SEC, most recently Nov 2024 ($26.0M sold to 2 investors).
- Status: Privately Held (backing).
Investors
1- ·Post-money valuations for all 1 rounds
- ·The complete investor list — 1 names
- ·Watchlist + deal alerts for Avenacy
Funding rounds
1 roundsAbout Avenacy
Operator of a pharmaceutical firm intended to make critical injectable medications. The company focuses on developing, manufacturing, and delivering critical medications used to treat patients in various settings, from acute care hospitals to outpatient clinics and physician offices, enabling doctors to treat patients with varying medical conditions.
- Sector
- Healthcare
- HQ
- Schaumburg, IL, United States
- Founded
- 2023
- Employees
- 26
- Website
- avenacy.com/
- Ownership
- Privately Held (backing)
Avenacy doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Avenacy shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Avenacy in its N-PORT filings yet. We sweep new filings monthly.